Pluxee Falls 3.73% at Close, Stock Penalized by Alphavalue's Revision
Pluxee closed down 3.73% at 11.37 euros this Thursday, January 15, penalized by a sharp reduction in Alphavalue's price target from 29.4 to 21 euros. The stock is in a technical oversold zone with an RSI at 30, despite the confirmation of the group's annual targets.
Continued Downtrend for Pluxee
Pluxee ended the trading session on Thursday, January 15, at 11.37 euros, down 3.73% from the previous day's close of 11.81 euros. The stock has continued its downward trajectory that began several weeks ago, now significantly below its support threshold established at 11.65 euros. This new contraction places the stock 16.6% below its 50-day moving average of 13.63 euros, confirming the establishment of a bearish technical trend. The RSI stands at 30, placing the stock in an oversold zone and indicating a short-term excess of pessimism. Over the week, the stock's performance reached -12.87%, while the decline over three months amounts to 23.59%. The 200-day moving average remains distant at 16.87 euros, representing a gap of 48% from the current price. The collapse over one year, reaching -49.24%, illustrates the magnitude of the correction suffered by the employee benefits specialist since its introduction in February 2024. This technical degradation occurs in a context where investors remain focused on regulatory uncertainties affecting Pluxee's business model, particularly in Brazil.
Alphavalue Drastically Lowers Price Target
Alphavalue lowered its price target to 21 euros from 29.4 euros this Thursday, marking a sharp revision of 28.6% that reflects the analysts' revised valuation expectations. This decision by the research firm comes even though the group had reported on January 7 a 9.0% organic revenue growth for the first quarter of fiscal 2026, confirming all its annual targets. For AlphaValue, the start of the year is encouraging, but regulatory risk remains the main obstacle to the stock's price development. Analysts' recommendations now display very contrasting targets: Citi maintains a target of 22 euros with a buy recommendation, while JP Morgan targets 18 euros with a neutral opinion, suggesting a theoretical recovery potential ranging between 58% and 93% relative to the current price of 11.37 euros. The immediate resistance threshold is at 13.62 euros, a level the stock must reclaim to initiate a technical rebound and break out of the downward spiral that began several weeks ago. The share of capital traded, limited to 0.2%, indicates reduced activity on the stock in a cautious market.
